BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 16157428)

  • 1. Genetic stability of recombinant MVA-BN.
    Timm A; Enzinger C; Felder E; Chaplin P
    Vaccine; 2006 May; 24(21):4618-21. PubMed ID: 16157428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation and evaluation of a recombinant modified vaccinia virus Ankara vaccine for rabies.
    Weyer J; Rupprecht CE; Mans J; Viljoen GJ; Nel LH
    Vaccine; 2007 May; 25(21):4213-22. PubMed ID: 17434244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic immunization with Modified Vaccinia Virus Ankara (MVA) vaccines in SIV-infected rhesus monkeys undergoing antiretroviral therapy.
    Uberla K; Rosenwirth B; Ten Haaft P; Heeney J; Sutter G; Erfle V
    J Med Primatol; 2007 Feb; 36(1):2-9. PubMed ID: 17359459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid generation of markerless recombinant MVA vaccines by en passant recombineering of a self-excising bacterial artificial chromosome.
    Cottingham MG; Gilbert SC
    J Virol Methods; 2010 Sep; 168(1-2):233-6. PubMed ID: 20417665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Construction of recombinant vaccinia virus expressing HSV-2 gD gene as live recombinant vaccine strain].
    Yan H; Rong M; Ruan L; Hou Y; He N; Zhu J
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Mar; 11(1):16-20. PubMed ID: 15619895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Construction and the immunogenicity of the recombinant Modified Vaccinia Virus Ankala co-expressing ORF4, ORF5 and ORF6 genes of porcine reproductive and Respiratory Syndrome Virus NJ-a strain].
    Zheng QS; Bi ZX; Li P; Chen DS; Chen PY
    Wei Sheng Wu Xue Bao; 2007 Apr; 47(2):345-9. PubMed ID: 17552247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
    Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M
    Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on in vitro expression and in vivo immunogenicity of a recombinant MVA HIV vaccine.
    Liu J; Wyatt LS; Amara RR; Moss B; Robinson HL
    Vaccine; 2006 Apr; 24(16):3332-9. PubMed ID: 16472543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microarray assay for evaluation of the genetic stability of modified vaccinia virus Ankara B5R gene.
    Laassri M; Meseda CA; Williams O; Merchlinsky M; Weir JP; Chumakov K
    J Med Virol; 2007 Jun; 79(6):791-802. PubMed ID: 17457926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya.
    Bejon P; Peshu N; Gilbert SC; Lowe BS; Molyneux CS; Forsdyke J; Lang T; Hill AV; Marsh K
    Clin Infect Dis; 2006 Apr; 42(8):1102-10. PubMed ID: 16575727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant murine gammaherpesvirus 68 (MHV-68) as challenge virus to test efficacy of vaccination against chronic virus infections in the mouse model.
    El-Gogo S; Staib C; Meyr M; Erfle V; Sutter G; Adler H
    Vaccine; 2007 May; 25(20):3934-45. PubMed ID: 17433507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Construction and biological characteristic for the recombinant modified vaccinia virus ankara co-expressing modified GP5 and M protein of porcine reproductive and respiratory syndrome virus].
    Zheng Q; Li P; Cao R; Hou J; Chen P
    Sheng Wu Gong Cheng Xue Bao; 2008 May; 24(5):766-73. PubMed ID: 18724695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Design and construction of transfer vectors in order to obtain recombinant modified vaccinia virus Ankara (MVA)].
    Ferrer MF; Zanetti FA; Calamante G
    Rev Argent Microbiol; 2007; 39(3):138-42. PubMed ID: 17987847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions.
    Veits J; Römer-Oberdörfer A; Helferich D; Durban M; Suezer Y; Sutter G; Mettenleiter TC
    Vaccine; 2008 Mar; 26(13):1688-96. PubMed ID: 18291561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different contribution of co-stimulatory molecules B7.1 and B7.2 to the immune response to recombinant modified vaccinia virus ankara vaccine expressing prM/E proteins of Japanese encephalitis virus and two hepatitis B virus vaccines.
    NAM JH; BANG HS; CHO HW; CHUNG YH
    Acta Virol; 2007; 51(2):125-30. PubMed ID: 17900219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques.
    Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
    J Infect Dis; 2009 Feb; 199(3):405-13. PubMed ID: 19061423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus.
    Martinon F; Brochard P; Ripaux M; Delache B; Aurégan G; Vaslin B; Le Grand R
    Vaccine; 2008 Jan; 26(4):532-45. PubMed ID: 18093703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction and isolation of recombinant MVA.
    Staib C; Drexler I; Sutter G
    Methods Mol Biol; 2004; 269():77-100. PubMed ID: 15114009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prime-boost vaccination using recombinant Mycobacterium bovis BCG and recombinant vaccinia virus DIs harboring HIV-1 CRF01_AE gag in mice: influence of immunization routes.
    Promkhatkaew D; Matsuo K; Pinyosukhee N; Thongdeejaroen W; Leang-Aramgul P; Sawanpanyalert P; Warachit P
    Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):273-81. PubMed ID: 19323012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.